Home > News

Follow Us

Increased risk of myocardial infarction

Genetically-elevated lipoprotein(a) levels and increased risk of myocardial infarction

In a recent publication, Kamstrup and colleagues (JAMA 2009; 301:2331-2339) present study results consistent with a causal association between elevated lipoprotein(a) levels and increased risk of myocardial infarction. 

 

Data from three studies of white individuals from Copenhagen, Denmark (CCHS, CIHDS and CIHDS) was used. In an editorial to this publication Thanassoulis and O'Donnell correspond that “this is an important biological finding that elevates the status of Lp(a)”.

For size independent measurement of lipoprotein(a)

 

Mercodia Lp(a) assay

(10-1106-01 Apo(a) ELISA)

Kit features:
nSpecific for human lipoprotein(a)
nMonoclonal antibodies for lot-to-lot consistency
nHigh precision
nEasy-to-use format
nAssay range: 0.3 – 5 U/l
nSample volume: 25μl
nSensitivity: 0.05 U/l
nIncubations: 60+60+15 min
nSamples: serum/plasma
n1x96 wells

 

Please read the article of Kamstrup and colleagues:

Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009). Genetically-elevated Lipoprotein (a) and increased risk of myocardial infarction. JAMA 301:2331-2339


Editorial:

Thanassoulis G and O'Donnell CJ (2009) Mendelian randomization. Nature's randomized trial in the post-genome era. JAMA 301:2386-2388

 

 

05/05/14 Combining two technologies may increase the effectiveness of oral insulin

04/10/14 Supplemental diets for cows benefit their performance

04/01/14 Mercodia announces collaboration with Chongqing Zhongyuan Biotechnology Co in China

03/20/14 Blocking Ca-ion flow alleviates hypoxia-induced damage to beta cells

03/10/14 NEW – Mercodia Launches Rat Glicentin ELISA

02/27/14 Glucagon WEBINAR with Professor Jens Juul Holst

More news and archive | Return | Print